NeuroPace (NPCE) CMO receives new RSU and stock option awards
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
NeuroPace Inc reported that Chief Medical Officer Martha Morrell received new equity awards. She acquired 5,460 shares of common stock in the form of restricted stock units, bringing her direct holdings to 52,743 shares of common stock.
She was also granted a stock option for 14,550 shares of common stock at an exercise price of $15.36 per share, expiring on May 14, 2036. The RSUs and options each vest 25% on May 15, 2027, with the remaining portions vesting over subsequent quarterly and monthly installments, respectively.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Morrell Martha
Role
CHIEF MEDICAL OFFICER
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 14,550 | $0.00 | -- |
| Grant/Award | Common Stock | 5,460 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 14,550 shares (Direct, null);
Common Stock — 52,743 shares (Direct, null)
Footnotes (1)
- Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 25% of the RSUs vest on May 15, 2027 and the remaining RSUs vest in twelve (12) equal quarterly installments thereafter. 25% of the shares subject to the option vest on May 15, 2027. The remaining shares subject to the option vest in thirty six (36) equal consecutive monthly installments thereafter.
Key Figures
RSU grant: 5,460 shares
Shares held after grant: 52,743 shares
Option grant size: 14,550 shares
+3 more
6 metrics
RSU grant
5,460 shares
Restricted stock units representing common stock granted on May 15, 2026
Shares held after grant
52,743 shares
Total common stock directly held after RSU award
Option grant size
14,550 shares
Stock option covering common stock granted on May 15, 2026
Option exercise price
$15.36 per share
Conversion or exercise price for new stock option
Option expiration
May 14, 2036
Expiration date of new stock option grant
Initial vesting date
May 15, 2027
25% of RSUs and 25% of option shares vest on this date
Key Terms
restricted stock unit, RSU, Stock Option (Right to Buy), vest, +1 more
5 terms
restricted stock unit financial
"Each share is represented by a restricted stock unit ("RSU")."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
RSU financial
"Each share is represented by a restricted stock unit ("RSU")."
Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
vest financial
"25% of the RSUs vest on May 15, 2027 and the remaining RSUs vest in twelve (12) equal quarterly installments thereafter."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercise price financial
"conversion_or_exercise_price: "15.3600""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
What equity awards did NeuroPace (NPCE) CMO Martha Morrell receive?
Martha Morrell received 5,460 restricted stock units and a stock option for 14,550 shares. The option has a $15.36 exercise price and both awards vest over time beginning May 15, 2027.
What is the exercise price and term of the new NeuroPace (NPCE) stock option?
The new stock option covers 14,550 shares at an exercise price of $15.36 per share. The option expires on May 14, 2036, giving a long-term window to exercise once vested.
When do Martha Morrell’s new NeuroPace (NPCE) RSUs vest?
Twenty-five percent of the 5,460 RSUs vest on May 15, 2027. The remaining RSUs then vest in twelve equal quarterly installments after that initial vesting date, subject to the award terms.
What is the vesting schedule for the new NeuroPace (NPCE) stock options?
Twenty-five percent of the option shares vest on May 15, 2027. The remaining option shares vest in thirty-six equal consecutive monthly installments thereafter, contingent on the conditions of the grant.
Is this NeuroPace (NPCE) Form 4 a purchase or a compensation grant?
The Form 4 reflects a compensation-related grant, not an open-market purchase. Both the RSUs and stock options were reported with transaction code A, indicating grant or award acquisitions to the Chief Medical Officer.